Muirhead N. Ann Intern Med. 2010 Jun 1;152(11):721-5
This article highlights the findings of several key trials that were published in the field of chronic kidney disease in 2009.
FDA notified healthcare professionals of revisions to the prescribing information for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. Byetta, an incretin-mimetic, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Hutchison CA, Basnayake K, Cockwell P. Nat Rev Nephrol. 2009 Nov;5(11):621-8
This review examines the evidence associated with the use of the free light chain assay.
Free full text access to the Harrison’s chapter “Alterations in Renal and Urinary Tract Function”.
Kripalani M, Shawcross J, Reilly J, Main J. BMJ. 2009 Jul 3;339:b2452
This review discusses the renal impact of lithium usage and offers guidance on monitoring, drug interactions, and when to consider discontinuation.
West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M, Barshop BA, Rhead W, Mensah R, Ries M, Schiffmann R. J Am Soc Nephrol. 2009 May;20(5):1132-9
Burgess E, Muirhead N, Rene de Cotret P, Chiu A, Pichette V, Tobe S, SMART (Supra Maximal Atacand Renal Trial) Investigators. J Am Soc Nephrol. 2009 Apr;20(4):893-900
El Fakih R, Saliba W, Mortada R. Am J Kidney Dis. 2009 Apr;53(4):xxxvii-xxxix
Chartapisak W, Opastiraku S, Willis NS, Craig JC, Hodson EM. Arch Dis Child. 2009 Feb;94(2):132-7
Cordova KB, Oberg TJ, Malik M, Robinson-Bostom L. Semin Dial. 2009 Jan-Feb;22(1):45-55
Kuypers DR. Nat Clin Pract Nephrol. 2009 Mar;5(3):157-70
Mantan M, Sharma S, Mishra D. Am J Kidney Dis. 2009 Mar;53(3):546-9
This website is supported through unrestricted funding provided by genzyme Corporation
Nephrology Now ISSN 1911-8880
© 2007-10 KM Medical, All Rights Reserved
Recent Comments